Trevi Therapeutics (TRVI) Non-Current Debt (2020 - 2022)

Trevi Therapeutics has reported Non-Current Debt for 3 years, with the latest figure at $2.2 million in Q4 2022.

• For the quarter ending Q4 2022, Non-Current Debt fell 75.14% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2022 stood at $2.2 million (down 75.14% YoY), and the FY2022 full-year result was $2.2 million, down 75.14% from the prior year.
• Non-Current Debt for Q4 2022 stood at $2.2 million, down from $3.8 million in the prior quarter.
• The five-year high for Non-Current Debt was $14.0 million in Q4 2020, with the low at $2.2 million in Q4 2022.
• Average Non-Current Debt over 3 years is $9.1 million, with a median of $9.4 million recorded in 2021.
• Year-over-year, Non-Current Debt fell 25.75% in 2021 and plunged 75.14% in 2022.
• Tracing TRVI's Non-Current Debt over 3 years: stood at $14.0 million in 2020, then slumped by 38.0% to $8.7 million in 2021, then sank by 75.14% to $2.2 million in 2022.
• The last three Non-Current Debt figures came in at $2.2 million (Q4 2022), $3.8 million (Q3 2022), and $5.4 million (Q2 2022), per Business Quant data.

Peer Comparison